Matt Kapusta, uniQure CEO
December 10, 2024 02:39 PM ESTUpdated 03:55 PM
Pharma
FDA+

UniQure stock dou­bles on FDA 'align­men­t' over ac­cel­er­at­ed ap­proval for Hunt­ing­ton's drug

Zachary Brennan

Senior Editor

Dutch-based uniQure saw its stock $QURE rise by more than 120% on Tues­day af­ter it dis­closed that it is “in align­ment” with the FDA on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times